02Aug
20Apr
Xylyx Bio Matrikynes Exhibits Clinical Anti-aging, Barrier Repair Efficacy
Xylyx Bio, a regenerative medicine company focused on technologies for organ and tissue repair, has released a white paper from an independent clinical study showing its Matrikynes ingredient (INCI: Not Provided), based on matrikines, is safe and highly effective for anti-aging and other topical skin care applications. Effects included reversing common signs of skin damage and aging, including the reduction of lines and wrinkles. Matrikynes is comprised of a mixture of natural extracellular matrix-derived peptides, i.e., matrikines. The intrinsic bioactivity...
06Apr
Clinical study shows Xylyx Bio’s Matrikynes® significantly improves the structure, function, and appearance of skin
Xylyx Bio, a regenerative medicine company developing breakthrough technologies for organ and tissue repair, today announced findings from an independent clinical study that validated that their proprietary Matrikynes® ingredient is safe and highly effective for anti-aging and other topical skin applications. Results from the study are reported in the white paper "Clinical evaluation of Matrikynes®: a novel cosmetic ingredient comprised of matrikine peptides". Developed through biomedical research aimed at better understanding and promoting tissue repair and wound healing, Matrikynes® is...
01Mar
Xylyx Bio launches new website to showcase growing portfolio of regenerative biotechnologies
Xylyx Bio, a New York-based regenerative medicine company leading the development of advanced biomaterials and biosystems, is proud to announce the launch of their redesigned website showcasing the company's growing portfolio of regenerative biotechnologies. Leveraging its core expertise in bioengineering, Xylyx Bio has expanded its developmental pipeline beyond advanced biomaterials for disease modeling and drug testing to include novel breakthrough technologies for tissue and organ regeneration. Read more >>
24Jan
Researchers confirm successful rehabilitation and recovery of human donor lungs previously deemed unfit for transplant
A novel method for supporting and recovering donor lungs outside the body shows potential to increase the number of organs available for transplant, according to a recent study published in The Journal of Heart and Lung Transplantation. The organ shortage crisis is increasingly dire, as thousands of patients die every year waiting to receive donor organs. Despite urgent demand, nearly 80% of donated lungs are too damaged for transplantation, often due to reversible conditions. A cross-disciplinary team of surgeons and...
06Apr
Xylyx Bio collaboration reveals new insights into tumor drug resistance
Xylyx Bio develops physiologic disease models that enable researchers to gain insights into tumor biology and evaluate the efficacy of drug candidates. Their IN SITE™ Metastasis Kit was recently featured in a publication for a study that showed that dietary interventions may increase the efficacy of treatment for breast cancer metastases. Metastatic breast cancer patients respond poorly to standard of care therapies due, in part, to the failure of conventional models to recreate the complex interactions between tumor cells and...
03Sep
Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute
Xylyx Bio, Inc., a biotechnology company developing groundbreaking solutions for drug discovery and tissue modeling and repair, announced today that it has been awarded a Small Business Innovation Research (SBIR) Fast-Track grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to advance development of an anti-fibrotic drug testing platform that will help scientists discover and test drug candidates for idiopathic pulmonary fibrosis (IPF). Read more >>
02Sep
Xylyx Bio partners with Inventia Life Science to develop tissue-specific, digitally-printed bioinks for drug discovery
Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. Read more >>
08Dec
From Conquering COVID-19 to Curing Cancer, New York City Charts the Future of Life Sciences
For the past 25 years, the public and private sectors have worked together to establish New York City as a global leader in life sciences research and innovation. Thanks to that coordinated effort, the city was able to respond to COVID-19 efficiently and effectively, becoming a model for other urban areas as COVID-19 cases peaked across the U.S.—and showcasing a burgeoning life sciences industry in the city that’s poised for future growth... New York life sciences companies continue to step...
30Sep